Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

5.18
-0.0850-1.61%
Volume:273.40K
Turnover:1.42M
Market Cap:144.29M
PE:-3.32
High:5.25
Open:5.24
Low:5.13
Close:5.27
52wk High:8.74
52wk Low:3.71
Shares:27.86M
Float Shares:27.23M
Volume Ratio:1.26
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.71
PE(LYR):-3.10

Loading ...

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 12

Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million

Reuters
·
May 12

Unicycive Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Reuters
·
May 09

Unicycive Therapeutics posts corporate presentation on kidney disease treatments

Reuters
·
May 05

B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target

MT Newswires Live
·
May 01

Unicycive Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

Unicycive director Gaurav Aggarwal resigns from board

Reuters
·
Apr 06

Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark

Dow Jones
·
Apr 06

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

TIPRANKS
·
Apr 06

Unicycive Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Apr 02

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

TIPRANKS
·
Apr 02

Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date

Reuters
·
Apr 02

Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate

Benzinga Earnings
·
Mar 30

Unicycive Therapeutics presentation highlights OLC NDA review for dialysis hyperphosphatemia treatment

Reuters
·
Mar 30

Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 30

Unicycive FY25 net loss narrows 28% to USD 27 million

Reuters
·
Mar 30

Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns

TIPRANKS
·
Mar 18

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Pipeline and OLC Hyperphosphatemia Program

Reuters
·
Mar 06

Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Mar 02